Tirzepatide in Chronic Kidney Disease: Evidence and Guideline Recommendations

Comparative Effectiveness in Renal and Cardiovascular Outcomes

In a retrospective cohort of 14,834 patients treated with tirzepatide versus 125,474 receiving GLP‑1 receptor agonists, tirzepatide was associated with a 42% reduction in all‑cause mortality (adjusted HR 0.58; 95 % CI 0.45‑0.75). American College of Endocrinology. 1
The same cohort showed a 48% lower risk of composite renal events (adjusted HR 0.52; 95 % CI 0.37‑0.73). American College of Endocrinology. 1
Tirzepatide reduced the incidence of acute kidney injury by 22% (adjusted HR 0.78; 95 % CI 0.70‑0.88). Kidney International. 2
Major adverse renal events were 46% less frequent with tirzepatide (adjusted HR 0.54; 95 % CI 0.44‑0.67). American College of Endocrinology. 1
Major adverse cardiovascular events were reduced by 20% (adjusted HR 0.80; 95 % CI 0.71‑0.91). American College of Endocrinology. 1

The American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) 2022 guidelines recommend GLP‑1 receptor agonists with proven cardiovascular benefit as the preferred add‑on therapy for CKD patients who do not achieve glycemic targets with metformin and/or SGLT2 inhibitors. [3][2]
According to the same ADA/KDIGO 2022 guidance, GLP‑1 agonists demonstrably reduce albuminuria and slow eGFR decline, based on secondary outcomes of cardiovascular outcome trials. [3][2]
Liraglutide, semaglutide, and dulaglutide have each shown cardiovascular benefit in large outcome trials, supporting their use in CKD populations. [3][2]
Gastro‑intestinal adverse events (nausea, vomiting, diarrhea) occur in 15‑20 % of patients with moderate‑to‑severe CKD (stages G3‑G4) but are generally manageable with dose titration. [3][2]

Although tirzepatide is not explicitly listed in the ADA/KDIGO 2022 recommendations, newer guidelines acknowledge its emerging role in CKD management. American College of Endocrinology (2025) and Diabetes Care (2025). [1][4]
The American Association of Clinical Endocrinology 2025 guideline recommends semaglutide as the preferred agent for CKD treatment, citing data that 1 mg weekly slows eGFR decline; this underscores the class effect of incretin‑based therapies. American College of Endocrinology. 1
A prospective clinical trial evaluating the primary renal impact of tirzepatide is currently underway; post‑hoc analysis of earlier type 2 diabetes studies suggests a favorable renal safety and efficacy profile. American College of Endocrinology. 1
The ADA 2025 guideline advises initiating GLP‑1 agonists and SGLT2 inhibitors in CKD patients when eGFR is >20 mL/min/1.73 m², reflecting confidence in their renal and cardiovascular benefits. Diabetes Care. 4